Metabolic Pathway-Targeted Therapy in ALS

🧫 Experiment Protocol ClinicalALSHK2/PLIN2/PPARGC1Ahumanproposed

# Metabolic Pathway-Targeted Therapy in ALS ## Background and Rationale This groundbreaking clinical trial represents a precision medicine approach to ALS therapy through comprehensive metabolic pathway targeting based on individual patient metabolomic profiles. Recent advances in systems biology have revealed profound metabolic dysregulation in ALS, including disrupted glucose metabolism, altered lipid homeostasis, and impaired mitochondrial bioenergetics. Rather than pursuing a one-size-fits-all approach, this study will stratify patients based on their unique metabolic signatures and apply targeted interventions including ketogenic dietary protocols, mitochondrial cofactor supplementation, and metabolic enzyme modulators. The trial leverages cutting-edge metabolomics technology to identify patient-specific metabolic vulnerabilities and match them with appropriate therapeutic interventions. The experimental framework incorporates longitudinal metabolomic profiling using mass spectrometry-based platforms to track over 1,000 metabolites across multiple pathways including glycolysis, TCA cycle, amino acid metabolism, and lipid biosynthesis. Patients will be stratified into distinct metabolic phenotypes using machine learning algorithms, with each group receiving tailored interventions. Outcome measures include traditional ALS functional rating scales alongside novel biomarkers of metabolic function, mitochondrial health, and cellular energetics. Advanced techniques including 31P-MRS will non-invasively assess brain energy metabolism, while muscle biopsies will evaluate mitochondrial respiratory capacity and metabolic enzyme activities. This personalized metabolic intervention strategy could establish a new therapeutic paradigm for ALS treatment based on individual metabolic profiles. This experiment directly tests predictions arising from the following hypotheses: - **Digital Twin-Guided Metabolic Reprogramming** - **AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses** - **Perforant Path Presynaptic Terminal Protection Strategy** - **Metabolic Switch Targeting for A1→A2 Repolarization** - **Metabolic Circuit Breaker via Lipid Droplet Modulation** ## Experimental Protocol **Phase 1: Patient Recruitment and Baseline Assessment (Months 1-3)** • Recruit 180 ALS patients (90 treatment, 90 placebo) meeting revised El Escorial criteria • Inclusion: Age 18-75, disease duration <2 years, ALSFRS-R score ≥30 • Exclusion: FVC <65%, significant comorbidities, prior riluzole intolerance • Conduct comprehensive baseline assessments: ALSFRS-R, FVC, grip strength, metabolomics panel • Obtain blood samples for targeted metabolomics (amino acids, lipids, glucose metabolism) • Perform MR spectroscopy for brain metabolite quantification **Phase 2: Metabolic Pathway Analysis and Stratification (Month 4)** • Analyze baseline metabolomics data using LC-MS/MS and GC-MS platforms • Identify dysregulated pathways: glutamate metabolism, mitochondrial function, lipid oxidation • Stratify patients based on metabolic phenotypes using unsupervised clustering • Randomize within strata to treatment (metabolic cocktail) vs placebo groups **Phase 3: Treatment Administration (Months 5-16)** • Administer daily metabolic cocktail: creatine (5g), coenzyme Q10 (300mg), α-lipoic acid (600mg) • Add targeted supplements based on individual metabolic deficits • Monitor compliance via pill counts and plasma biomarker levels • Collect safety data monthly: liver function, renal function, adverse events **Phase 4: Efficacy Monitoring (Months 5-18)** • Monthly ALSFRS-R assessments and pulmonary function testing • Quarterly muscle strength testing (handheld dynamometry, grip strength) • Semi-annual MR spectroscopy and comprehensive metabolomics analysis • Continuous monitoring of survival and time to ventilatory assistance **Phase 5: Data Analysis and Validation (Months 17-18)** • Primary endpoint: Rate of ALSFRS-R decline over 12 months • Secondary analyses: Survival, FVC decline, biomarker normalization • Validate metabolic pathway restoration using targeted and untargeted metabolomics • Perform responder analysis based on metabolic phenotypes ## Expected Outcomes 1. **Primary Efficacy**: 35% reduction in ALSFRS-R decline rate (from 1.1 to 0.7 points/month) in treatment group compared to placebo (effect size d=0.6) 2. **Metabolic Restoration**: Normalization of ≥60% of baseline dysregulated metabolites in responder subgroup, with particular improvement in glutamate/GABA ratio and mitochondrial metabolites 3. **Functional Preservation**: 25% slower decline in forced vital capacity and 30% preservation of grip strength compared to placebo group over 12-month treatment period 4. **Survival Benefit**: 4-month median survival extension and 40% reduction in time to non-invasive ventilation requirement in treatment group 5. **Biomarker Response**: Dose-dependent increase in plasma creatine kinase activity and CoQ10 levels, correlating with clinical response (r>0.5) 6. **Phenotype-Specific Response**: Patients with severe baseline metabolic dysfunction showing 50% greater treatment response compared to those with mild dysfunction ## Success Criteria • **Primary Endpoint Achievement**: Statistically significant difference (p<0.05) in ALSFRS-R decline rate between treatment and placebo groups with effect size ≥0.5 • **Metabolic Target Engagement**: ≥50% of treatment group showing normalization of at least 3 key metabolic pathways (glutamate, mitochondrial, lipid) with p<0.01 • **Clinical Meaningfulness**: Minimum 20% reduction in disease progression rate with 95% confidence interval excluding null effect • **Safety Profile**: <15% treatment-related adverse events and no serious adverse events attributable to intervention with safety monitoring board approval • **Biomarker Validation**: Significant correlation (r>0.4, p<0.01) between metabolic pathway restoration and clinical response measures • **Sample Size Adequacy**: ≥85% patient retention through 12-month primary endpoint with <10% missing data for primary outcome analysis

Source: wiki

🧫 Experiment Extras

🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found